FDA OK's Pfizer/Ligand hot flash, osteoporosis drug Duavee
This article was originally published in Scrip
Executive Summary
The fact that it was operating with only about half its staff during a government shutdown did not keep the US FDA from approving new medicines this week – granting Pfizer the OK to market its hot flash and osteoporosis drug Duavee (conjugated estrogens/bazedoxifene), the pharma giant revealed on 3 October.